Search Results - BRUGAROLAS, ANTONIO

Refine Results
  1. 1

    RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer by Manzano, Ramon Gonzalez, Catalan-Latorre, Ana, Brugarolas, Antonio

    Published in BMC cancer (20-04-2021)
    “…Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53 somatic alterations in a variable percentage of tumors throughout all molecular…”
    Get full text
    Journal Article
  2. 2

    Psycho-Oncological Intervention Through Counseling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine (COUNTHY, NCT05054634): A Non-randomized Controlled Study by Javaloyes, Nuria, Crespo, Aurora, Redal, M Carmen, Brugarolas, Antonio, Botella, Lara, Escudero-Ortiz, Vanesa, Sureda, Manuel

    Published in Frontiers in psychology (25-02-2022)
    “…Diagnosis and treatment of differentiated thyroid carcinomas (DTC) cause anxiety and depression. Additionally, these patients suffer hormonal alterations that…”
    Get full text
    Journal Article
  3. 3

    Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies by Mata-Molanes, Juan J., Rebollo-Liceaga, Joseba, Martínez-Navarro, Elena Mª, Manzano, Ramón González, Brugarolas, Antonio, Juan, Manel, Sureda, Manuel

    Published in Frontiers in oncology (24-06-2022)
    “…Therapeutic monoclonal antibodies (mAbs), including immune checkpoint inhibitors (ICIs), are an important breakthrough for the treatment of cancer and have…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study by Catalán-Latorre, Ana, Sureda, Manuel, Brugarolas-Masllorens, Antonio, Escudero-Ortiz, Vanesa

    Published in Therapeutic drug monitoring (01-08-2021)
    “…We describe a clinical case of an 84-year-old man diagnosed with non-small cell lung carcinoma and epidermal growth factor receptor mutation, who was treated…”
    Get full text
    Journal Article
  6. 6

    Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience by Sureda, Manuel, Catalán-Latorre, Ana, Mata, Juan José, Escudero, Vanesa, Brugarolas, Antonio

    Published in Journal of clinical oncology (20-05-2019)
    “…Abstract only e14089 Background: Fixed dose schemes, regardless of body weight, have been accepted by the regulatory agencies for the PD-1 targeting…”
    Get full text
    Journal Article
  7. 7

    A novel genomic signature predicting FDG uptake in diverse metastatic tumors by Crespo-Jara, Aurora, Redal-Peña, Maria Carmen, Martinez-Navarro, Elena Maria, Sureda, Manuel, Fernandez-Morejon, Francisco Jose, Garcia-Cases, Francisco J., Manzano, Ramon Gonzalez, Brugarolas, Antonio

    Published in EJNMMI research (18-01-2018)
    “…Background Building a universal genomic signature predicting the intensity of FDG uptake in diverse metastatic tumors may allow us to understand better the…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs by Crespo-Jara, Aurora, González Manzano, Ramón, Lopera Sierra, Maribel, Redal Peña, María Carmen, Brugarolas Masllorens, Antonio

    Published in Clinical nuclear medicine (01-09-2016)
    “…ABSTRACTWe present a sarcoma patient with a tumor reduction of more than 50% in lung metastasis after 2 single courses of the investigational medical product…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13

    Immunological profile could be responsible of the unusual long-lasting cutaneous-only breast cancer recurrence: An observational study by Rebollo, Joseba, González-Manzano, Ramón, Sureda, Manuel, Martínez, Elena Ma, Monedero, Elena, Bretcha, Pedro, Brugarolas, Antonio

    Published in Journal of clinical oncology (01-06-2022)
    “…e13000 Background: A small number of breast cancer patients develops long-lasting loco-regional cutaneous recurrent disease with a delayed appearance of…”
    Get full text
    Journal Article
  14. 14

    Colorectal Carcinomas and PTEN/MMAC1 Gene Mutations by DICUONZO, Giordano, ANGELETTI, Silvia, GARCIA-FONCILLAS, Jesus, BRUGAROLAS, Antonio, OKROUZHNOV, Yuri, SANTINI, Daniele, TONINI, Giuseppe, LORINO, Giulia, DE CESARIS, Marina, BALDI, Alfonso

    Published in Clinical cancer research (01-12-2001)
    “…Purpose: PTEN/MMAC1/TEP1 is a tumor suppressor gene encoding a dual-specificity protein phosphatase with homology to the cytoskeleton proteins, chicken tensin…”
    Get full text
    Journal Article
  15. 15

    Abstract 4648: Development and validation of an HPLC-UV method for Sirolimus (sir) quantification in human blood and application to cancer patients in routine clinical practice by Escudero-Ortiz, Vanesa, Valenzuela, Belen, Rebollo, Joseba, Sureda, Manuel, Brugarolas, Antonio

    Published in Cancer research (Chicago, Ill.) (01-10-2014)
    “…Background and objective: After oral administration, SIR (mTOR inhibitor) is rapid absorbed with a bioavailability around 14%. SIR is distributed mostly into…”
    Get full text
    Journal Article
  16. 16

    Equilibrative Nucleoside Transporter ENT1 as a Biomarker of Huntington Disease by Guitart, Xavier, Bonaventura, Jordi, Rea, William, Orrú, Marco, Cellai, Lucrezia, Dettori, Ilaria, Pedata, Felicita, Brugarolas, Marc, Cortés, Antonio, Casadó, Vicent, Chang, Ching-Pang, Narayanan, Manikandan, Chern, Yijuang, Ferré, Sergi

    Published in Neurobiology of disease (01-12-2016)
    “…Abstract The initial goal of this study was to investigate alterations in adenosine A2A receptor (A2A R) density or function in a rat model of Huntington…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Abstract 762: Therapeutic drug monitoring of Anthracyclines and Taxanes in chemotherapy of breast cancer patients by Valenzuela, Belén, Escudero, Vanesa, Rebollo, Joseba, Sureda, Manuel, Brugarolas, Antonio

    Published in Cancer research (Chicago, Ill.) (15-04-2012)
    “…Background: Anthracyclines (A) and Taxanes (T) remain amongst the most active drugs in breast cancer chemotherapy. However, significant toxicities are…”
    Get full text
    Journal Article
  19. 19

    Transcriptome (RNA next generation sequencing) for personalizing of cancer treatment: A correlation with previous clinical resistance by Sureda, Manuel, Rebollo, Joseba, González-Manzano, Ramón, Martínez, Elena Ma, Rostagno, Roman, Mata, Juan José, Monedero, Elena, Ortega, Jose, Brugarolas, Antonio

    Published in Journal of clinical oncology (20-05-2021)
    “…Abstract only e15046 Background: RNA Next Generation Sequencing (transcriptome) is a potential useful tool to predict chemoresistance to available anticancer…”
    Get full text
    Journal Article
  20. 20

    A phase II study of Recchia's immunomodulatory schedule (RIS) as a maintenance therapy in high-risk tumors after a response by Sureda, Manuel, Rebollo, Joseba, Vazquez, Begona, Bretcha, Pere, Cañon, Rosa, Duarte, Maritza, Munoz, Vicente, Brugarolas, Antonio

    Published in Journal of clinical oncology (20-05-2013)
    “…Abstract only 3074 Background: F. Recchia et al. (Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: A phase II study. Int J…”
    Get full text
    Journal Article